Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17700697 | 0.93 | MAPT (0.44) | TRIM24TYRTRIM33FFAR4ALDH1A1 | |
| SCHEMBL20424771 | 0.84 | ALDH1A1 (0.48) | TRIM24TYRTRIM33ALDH1A1KMT2A | |
| SCHEMBL20522567 | 0.83 | ALDH1A1 (0.40) | TRIM24TYRTRIM33FFAR4ALDH1A1 | |
| SCHEMBL2427187 | 0.82 | ALDH1A1 (0.52) | FFAR4ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL24646041 | 0.81 | ALDH1A1 (0.52) | TRIM24TYRTRIM33FFAR4ALDH1A1 | |
| SCHEMBL17871817 | 0.81 | ALDH1A1 (0.56) | TRIM24TYRTRIM33ALDH1A1KMT2A | |
| SCHEMBL31151016 | 0.80 | HTR1A (0.44) | FFAR4KMT2AMEN1MAPT | |
| SCHEMBL17700319 | 0.80 | PTPN1 (0.39) | KMT2AERN1PTPN1 | |
| SCHEMBL20424643 | 0.80 | FFAR1 (0.43) | TRIM24TYRTRIM33ALDH1A1KMT2A | |
| SCHEMBL31636002 | 0.80 | ALDH1A1 (0.46) | FFAR4ALDH1A1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968231-B2 | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | SCOHIA PHARMA, INC. (JP) | 2021-04-06 | — | — | US | disclosed |
| US-20200377509-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-03 | — | — | US | disclosed |
| EP-3601260-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2020-02-05 | — | — | EP | disclosed |
| CN-110678458-A | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | 武田药品工业株式会社 | 2020-01-10 | — | — | CN | disclosed |
| WO-2018182050-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968231-B2 | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | GLP1R, GPR119, GPR65 | TRIM24 1414/4885TYR 3000/4885TRIM33 1050/4885 |
| US-20200377509-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GLP1R, GPR119, GPR65 | TRIM24 1414/4885TYR 3000/4885TRIM33 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.